Safety of ultrasound-guided transrectal extended prostate biopsy in patients receiving low-dose aspirin

International Braz J Urol

Volumn 36, Issue 3, 2010, Pages 308-316

  Kariotis, Ioannis ^a   Philippou, Prodromos ^a   Volanis, Demetrios ^a   Serafetinides, Efraim ^a   Delakas, Demetrios ^a  

^a IASO GENERAL HOSPITAL   (Greece)

Author keywords

Aspirin; Biopsy; Prostate; Transrectal

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

AGED; ARTICLE; COMPARATIVE STUDY; HEMOSPERMIA; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; POSTOPERATIVE HEMORRHAGE; PROSTATE; PROSTATE TUMOR; RISK FACTOR; STATISTICAL MODEL;

AGED; ASPIRIN; BIOPSY, NEEDLE; HEMOSPERMIA; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE HEMORRHAGE; PROSTATE; PROSTATIC NEOPLASMS; RISK FACTORS; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL;

EID: 77956130630     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-55382010000300007     Document Type: Article

References (22)

1. Terris MK: Sensitivity and specificity of sextant biopsies in the detection of prostate cancer: preliminary report. Urology. 1999; 54: 486-9.
2. Berger AP, Gozzi C, Steiner H, Frauscher F, Varkarakis J, Rogatsch H, et al.: Complication rate of transrectal ultrasound guided prostate biopsy: a comparison among 3 protocols with 6, 10 and 15 cores. J Urol. 2004; 171: 1478-80; discussion 1480-1.
3. Mariappan P, Chong WL, Sundram M, Mohamed SR: Increasing prostate biopsy cores based on volume vs the sextant biopsy: a prospective randomized controlled clinical study on cancer detection rates and morbidity. BJU Int. 2004; 94: 307-10.
4. Nesrallah L, Nesrallah A, Antunes AA, Leite KR, Srougi M: The role of extended prostate biopsy on prostate cancer detection rate: a study performed on the bench. Int Braz J Urol. 2008; 34: 563-70; discussion 570-1.
5. Masood J, Hafeez A, Calleary J, Barua JM: Aspirin use and transrectal ultrasonography-guided prostate biopsy: a national survey. BJU Int. 2007; 99: 965-6.
6. Connor SE, Wingate JP: Management of patients treated with aspirin or warfarin and evaluation of haemostasis prior to prostatic biopsy: a survey of current practice amongst radiologists and urologists. Clin Radiol. 1999; 54: 598-603.
7. Tobias-Machado M, Verotti MJ, Aragao AJ, Rodrigues AO, Borrelli M, Wroclawski ER: Prospective randomized controlled trial comparing three different ways of anesthesia in transrectal ultrasound-guided prostate biopsy. Int Braz J Urol. 2006; 32: 172-9; discussion 179-80.
8. Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schrder FH: Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology. 2002; 60: 826-30.
9. Peyromaure M, Ravery V, Messas A, Toublanc M, Boccon-Gibod L, Boccon-Gibod L: Pain and morbidity of an extensive prostate 10-biopsy protocol: a prospective study in 289 patients. J Urol. 2002; 167: 218-21.
10. Mkinen T, Auvinen A, Hakama M, Stenman UH, Tammela TL: Acceptability and complications of prostate biopsy in population-based PSA screening versus routine clinical practice: a prospective, controlled study. Urology. 2002; 60: 846-50.
11. Djavan B, Waldert M, Zlotta A, Dobronski P, Seitz C, Remzi M, et al.: Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol. 2001; 166: 856-60.
12. Ferrari E, Benhamou M, Cerboni P, Marcel B: Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol. 2005; 45: 456-9.
13. Maulaz AB, Bezerra DC, Michel P, Bogousslavsky J: Effect of discontinuing aspirin therapy on the risk of brain ischemic roke. Arch Neurol. 2005; 62: 1217-20.
14. Burger W, Chemnitius JM, Kneissl GD, Rücker G: Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. J Intern Med. 2005; 257: 399-414.
15. Maan Z, Cutting CW, Patel U, Kerry S, Pietrzak P, Perry MJ, et al.: Morbidity of transrectal ultrasonography-guided prostate biopsies in patients after the continued use of low-dose aspirin. BJU Int. 2003; 91: 798-800.
16. Giannarini G, Mogorovich A, Valent F, Morelli G, De Maria M, Manassero F, et al.: Continuing or discontinuing low-dose aspirin before transrectal prostate biopsy: results of a prospective randomized trial. Urology. 2007; 70: 501-5.
17. Halliwell OT, Yadegafar G, Lane C, Dewbury KC: Transrectal ultrasound-guided biopsy of the prostate: aspirin increases the incidence of minor bleeding complications. Clin Radiol. 2008; 63: 557-61.
18. Hankey GJ, Eikelboom JW: Aspirin resistance. Lancet. 2006; 367: 606-17.
19. Michos ED, Ardehali R, Blumenthal RS, Lange RA, Ardehali H: Aspirin and clopidogrel resistance. Mayo Clin Proc. 2006; 81: 518-26.
20. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345: 494-502. Erratum in: N Engl J Med 2001; 345: 1716. N Engl J Med 2001; 345: 1506.
21. Greenblatt DJ, Abernethy DR, Boxenbaum HG, Matlis R, Ochs HR, Harmatz JS, et al.: Influence of age, gender, and obesity on salicylate kinetics following single doses of aspirin. Arthritis Rheum. 1986; 29: 971-80.
22. Tamminen M, Lassila R, Westerbacka J, Vehkavaara S, Yki-Järvinen H: Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects. Int J Obes Relat Metab Disord. 2003; 27: 907-11.